Stock listing
BCAB Stock Price, News, Filings & Events — Bioatla, Inc.
Selected listing: BCAB · NASDAQ · USD · US
This page tracks Bioatla, Inc.'s BCAB:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BCAB:NASDAQ. BCAB:NASDAQ is the stock-level entry point for investors researching Bioatla, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Bioatla, Inc. is a public company traded under the ticker BCAB in the American market. The company has a market capitalization of approximately $5.59 million. Bioatla focuses on developing innovative therapies in the biotechnology sector.
- Ticker
- BCAB:NASDAQ
- Asset type
- Stock
- Market cap
- $2.9M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Bioatla, Inc. BCAB:NASDAQ stock context
This page tracks Bioatla, Inc.'s BCAB:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BCAB:NASDAQ. BCAB:NASDAQ is the stock-level entry point for investors researching Bioatla, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Bioatla, Inc. is a public company traded under the ticker BCAB in the American market. The company has a market capitalization of approximately $5.59 million. Bioatla focuses on developing innovative therapies in the biotechnology sector.
Latest news from Bioatla, Inc.
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 31, 2026
BioAtla Announces Share Consolidation
March 31, 2026
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
March 2, 2026
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Reg...
December 31, 2025
Bioatla, Inc. earnings calls
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call
November 13, 2025 · Replay with transcript and chapters
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call
August 7, 2025 · Replay with transcript and chapters
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call
May 6, 2025 · Replay with transcript and chapters
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call
March 27, 2025 · Replay with transcript and chapters
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call
November 7, 2024 · Replay with transcript and chapters
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call
August 8, 2024 · Replay with transcript and chapters
Research Bioatla, Inc.
Bioatla, Inc. investor report
Review AI stock analysis and investor report context for BCAB:NASDAQ.
Bioatla, Inc. company profile
View the public company page for Bioatla, Inc. on 6ix.
Bioatla, Inc. news
Read company news and market updates connected to Bioatla, Inc..
Bioatla, Inc. investor events
Find investor webinars, events, and replay context for Bioatla, Inc..